Moderna Inc.'s shares dropped over 13% premarket after FDA's top vaccine official Peter Marks resigned under pressure from the Trump administration, highlighting the sensitive inte...
Moderna Inc.'s shares dropped over 13% premarket after FDA's top vaccine official Peter Marks resigned under pressure from the Trump administration, signaling potential regulatory ...
Moderna Inc.'s shares dropped over 13% premarket after FDA's top vaccine official Peter Marks resigned under pressure from the Trump administration, highlighting the biotech sector...
Moderna Inc.'s stock fell over 13% premarket following the resignation of FDA's top vaccine official, Peter Marks, amid reports of being forced out by the Trump administration. The...
Moderna Inc.'s shares dropped over 13% premarket after FDA's top vaccine official Peter Marks resigned under pressure from the Trump administration, highlighting significant market...
Moderna Inc.'s shares dropped over 13% in premarket trading after the resignation of FDA's top vaccine official, Peter Marks, who was reportedly forced out by the Trump administrat...
A Dusseldorf court ruled in favor of Moderna in a patent dispute against Biontech and Pfizer, ordering them to disclose profits and compensate for unauthorized use of patented mRNA...
Moderna secures a significant legal victory in a patent dispute against Biontech and Pfizer, with a Dusseldorf court ruling in its favor. The dispute centers around the unauthorize...
Moderna Inc. reports a 65% drop in Q4 revenue to $966 million, with a net loss of $1.1 billion. Despite challenges, Spikevax sales hit $923 million, and the company plans significa...
Moderna Inc. revises its 2025 revenue forecast downwards to between $1.5 billion and $2.5 billion, citing a slow RSV vaccine rollout and decreased COVID-19 vaccine demand, leading ...
